Ivím Health review

Published research, with an FDA warning to read alongside it

Ivím offers an ongoing care membership with provider access, coaching and an app. Its published research makes it worth examining beyond a price card. There is also a material regulatory concern: FDA issued a February 20, 2026 warning letter to Ivim Services LLC dba Ivim. The agency said labels pictured on the company’s website misleadingly identified Ivím as the compounder of semaglutide and tirzepatide when it was not. Ask which pharmacy would make and dispense your prescription. Published outcomes do not resolve that labeling finding.

The membership buys access; medication is another bill

The membership page advertises $75 per month and explicitly separates medication charges. It describes an employed care team, check-ins and treatment adjustments. The homepage advertises unlimited same-day provider visits; the services page describes video appointments and e-visits. I would ask how to reach the prescribing team for symptoms and what appointment availability means for my state, rather than interpret unlimited access as a standing appointment or guaranteed immediate response.

The homepage now promotes twelve-month medication plans, while separate six-month offer pages remain available. These are different commitments, and neither medication figure is an all-inclusive monthly bill. Confirm the complete initial payment, membership obligation, supply and renewal amount for the actual plan. The cash-cost guide explains why an attractive monthly equivalent should be read beside its required fees and term. Ivím also advertises hormone-health programs; it is no longer accurately described as a GLP-1-only service.

Who is inside the outcome numbers?

The semaglutide paper analyzed 1,131 patients who had completed at least a year of treatment. Inclusion required reaching the specified target dose and staying with the same branded or compounded formulation without treatment gaps. The reported 21.8% average loss at 68 weeks concerned the smaller group of 822 patients with that longer follow-up. The separate tirzepatide paper included 1,166 year-long completers, also selected for continuous treatment and dose criteria. These were retrospective observational studies, not randomized trials of the membership or all new patients.

That selection changes how I read a success-rate headline: it does not include everyone who enrolled and then stopped early. Self-reported weights, incomplete measurements at particular time points and a smaller later-follow-up sample add uncertainty. Both papers were funded by Ivím; the authors disclosed company employment and a cofounder’s financial interest. Their findings describe selected patients’ results, but cannot establish that the membership caused better outcomes than another provider or a pharmaceutical trial.

Results in mostly women are not a maternal-care study

Both cohorts were predominantly female, but that does not make them evidence for postpartum or breastfeeding treatment. The semaglutide study’s protocol excluded people currently pregnant or breastfeeding. I would discuss the actual product and my circumstances with the clinical team instead of borrowing a cohort average as a personal forecast. The postpartum guide separates those timing questions from the appeal of a weight-loss result. Likewise, an observational comparison cannot establish that compounded and approved formulations are interchangeable; the brand-versus-compounded guide explains that distinction.

Canceling membership and unwinding a program are different

The membership agreement requires cancellation notice at least 48 hours before renewal. Canceling does not pause the program’s expiry clock or automatically return money already paid. The terms describe refunds for unshipped medication minus fees tied to the remaining portions, with an exception when a provider determines medical ineligibility. The refund policy separately says prescribed medications are non-refundable and refers back to those cancellation terms. Ask what applies to medication already prepared, future shipments and your remaining membership payments before committing.

For a potentially long treatment, the useful question is whether the care access and full agreement fit your needs. I would want a clear follow-up route and a plan for an interruption, not a promise of matching the study average. The stopping-treatment guide can help frame that conversation before an annual medication offer becomes the deciding factor.